{"analyses":[{"ciLowerLimit":"0.313","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.582","estimateComment":"Stratified analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.427","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.79","upperLimit":"4.17","value":"3.02"},{"groupId":"OG001","lowerLimit":"1.45","upperLimit":"2.73","value":"1.61"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"95"}],"units":"Participants"}],"description":"Time to radiographic progression is defined as the time from the date of randomization to the date of first observation of objective progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"8 mg/kg ramucirumab administered as an IV injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + BSC"},{"description":"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.\n\nParticipants still on treatment at the time of study completion may have the option to crossover to the ramucirumab arm.","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEDIAN","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"From Randomization to Objective Progression (Up to 28 Months)","title":"Time to Radiographic Progression","type":"SECONDARY","unitOfMeasure":"Months"}